EGFR and lung adenocarcinoma: We first collected the 3,243 tumors data of lung adenocarcinoma patients in China and several rarely reported mutations, including EGFR mutations (V742I, I789M, N842H) related with erlotinib, gefitinib, lapatinib, and EGFR mutations (S811C) related with afatinib were discovered (Table 5, Figure 3) by filtered in 800 potential druggable mutations of Hotspot3D.